Tonix Pharmaceuticals (TNXP) Competitors $39.01 +1.33 (+3.53%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$40.10 +1.09 (+2.79%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TNXP vs. NTLA, WVE, CDTX, AUPH, CVAC, PAHC, CALT, PRAX, SRPT, and SANAShould you be buying Tonix Pharmaceuticals stock or one of its competitors? The main competitors of Tonix Pharmaceuticals include Intellia Therapeutics (NTLA), WAVE Life Sciences (WVE), Cidara Therapeutics (CDTX), Aurinia Pharmaceuticals (AUPH), CureVac (CVAC), Phibro Animal Health (PAHC), Calliditas Therapeutics AB (publ) (CALT), Praxis Precision Medicines (PRAX), Sarepta Therapeutics (SRPT), and Sana Biotechnology (SANA). These companies are all part of the "pharmaceutical products" industry. Tonix Pharmaceuticals vs. Its Competitors Intellia Therapeutics WAVE Life Sciences Cidara Therapeutics Aurinia Pharmaceuticals CureVac Phibro Animal Health Calliditas Therapeutics AB (publ) Praxis Precision Medicines Sarepta Therapeutics Sana Biotechnology Tonix Pharmaceuticals (NASDAQ:TNXP) and Intellia Therapeutics (NASDAQ:NTLA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends. Which has more risk & volatility, TNXP or NTLA? Tonix Pharmaceuticals has a beta of 1.7, indicating that its share price is 70% more volatile than the S&P 500. Comparatively, Intellia Therapeutics has a beta of 2.31, indicating that its share price is 131% more volatile than the S&P 500. Is TNXP or NTLA more profitable? Intellia Therapeutics has a net margin of -1,154.10% compared to Tonix Pharmaceuticals' net margin of -1,313.87%. Intellia Therapeutics' return on equity of -56.06% beat Tonix Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Tonix Pharmaceuticals-1,313.87% -120.96% -101.28% Intellia Therapeutics -1,154.10%-56.06%-44.25% Which has preferable valuation & earnings, TNXP or NTLA? Tonix Pharmaceuticals has higher earnings, but lower revenue than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTonix Pharmaceuticals$10.04M28.58-$130.04M-$1.96 thousand-0.02Intellia Therapeutics$57.88M20.56-$519.02M-$5.23-2.20 Does the media prefer TNXP or NTLA? In the previous week, Intellia Therapeutics had 2 more articles in the media than Tonix Pharmaceuticals. MarketBeat recorded 10 mentions for Intellia Therapeutics and 8 mentions for Tonix Pharmaceuticals. Tonix Pharmaceuticals' average media sentiment score of 0.86 beat Intellia Therapeutics' score of 0.73 indicating that Tonix Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tonix Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Intellia Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders have more ownership in TNXP or NTLA? 82.3% of Tonix Pharmaceuticals shares are held by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are held by institutional investors. 0.0% of Tonix Pharmaceuticals shares are held by company insiders. Comparatively, 3.1% of Intellia Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Do analysts prefer TNXP or NTLA? Tonix Pharmaceuticals presently has a consensus target price of $70.00, suggesting a potential upside of 79.44%. Intellia Therapeutics has a consensus target price of $33.37, suggesting a potential upside of 190.41%. Given Intellia Therapeutics' higher probable upside, analysts clearly believe Intellia Therapeutics is more favorable than Tonix Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tonix Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Intellia Therapeutics 1 Sell rating(s) 6 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.65 SummaryIntellia Therapeutics beats Tonix Pharmaceuticals on 12 of the 17 factors compared between the two stocks. Get Tonix Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TNXP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TNXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TNXP vs. The Competition Export to ExcelMetricTonix PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$287.00M$2.46B$5.48B$9.51BDividend YieldN/A1.81%4.73%4.09%P/E Ratio-0.028.9728.6723.80Price / Sales28.58437.63373.9066.58Price / CashN/A157.7635.4557.96Price / Book1.234.838.275.55Net Income-$130.04M$31.62M$3.24B$259.03M7 Day Performance-21.54%-5.28%-3.69%-4.59%1 Month Performance10.92%4.38%4.33%4.46%1 Year Performance-18.66%-2.49%25.95%18.03% Tonix Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TNXPTonix Pharmaceuticals3.4271 of 5 stars$39.01+3.5%$70.00+79.4%-24.9%$287.00M$10.04M-0.0250Analyst RevisionGap DownNTLAIntellia Therapeutics4.501 of 5 stars$12.96+1.4%$33.37+157.4%-54.3%$1.32B$45.57M-2.44600News CoverageUpcoming EarningsGap DownWVEWAVE Life Sciences4.7497 of 5 stars$8.22-2.0%$20.15+145.2%+40.1%$1.28B$104.94M-9.82240News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionCDTXCidara Therapeutics3.1487 of 5 stars$62.790.0%$57.29-8.8%+389.1%$1.27B$302K-2.1390Upcoming EarningsAUPHAurinia Pharmaceuticals2.3298 of 5 stars$9.10+0.3%$11.50+26.4%+87.0%$1.23B$247.30M32.42300Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionCVACCureVac4.4438 of 5 stars$5.45+0.1%$6.83+25.5%+51.1%$1.22B$579.18M5.92880News CoveragePositive NewsPAHCPhibro Animal Health4.1332 of 5 stars$29.58+0.5%$24.40-17.5%+41.1%$1.20B$1.19B38.081,940Positive NewsDividend AnnouncementCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180PRAXPraxis Precision Medicines2.4185 of 5 stars$57.49-0.9%$94.11+63.7%-5.0%$1.17B$8.55M-5.36110Analyst ForecastSRPTSarepta Therapeutics4.71 of 5 stars$11.77-8.7%$51.42+337.0%-89.0%$1.16B$1.90B-4.381,372Trending NewsUpcoming EarningsAnalyst ForecastOptions VolumeSANASana Biotechnology3.3036 of 5 stars$4.94-3.8%$9.17+85.7%-27.1%$1.12BN/A-5.64380News CoverageUpcoming EarningsGap Down Related Companies and Tools Related Companies Intellia Therapeutics Alternatives WAVE Life Sciences Alternatives Cidara Therapeutics Alternatives Aurinia Pharmaceuticals Alternatives CureVac Alternatives Phibro Animal Health Alternatives Calliditas Therapeutics AB (publ) Alternatives Praxis Precision Medicines Alternatives Sarepta Therapeutics Alternatives Sana Biotechnology Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TNXP) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tonix Pharmaceuticals Holding Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tonix Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
